Prevalence and long-term outcomes of NAFLD and cardiovascular-kidney-metabolic health in the United States
American Journal of Preventive Cardiology · 2025-09 · 23 · 101049
DOI: 10.1016/j.ajpc.2025.101049 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2025-09. Verfasst von Jian Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine, Chongqing University, Chongq…. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims: To explore non-alcoholic fatty liver disease (NAFLD)'s role within the novel cardiovascular-kidney-metabolic (CKM) syndrome framework, given their overlapping pathophysiological mechanisms.
Methods
We analyzed 10,985 U.S. adults from the National Health and Nutrition Examination Survey III (1988-1994), with mortality follow-up until 2019. NAFLD was assessed via ultrasonography, and liver fibrosis was determined by the NAFLD fibrosis score and Fibrosis-4 index. CKM stages and predicted cardiovascular (CVD) event risk were assessed per American Heart Association guidelines.
Results
Age-standardized prevalence of NAFLD progressively increased across CKM stages, from 21.8 % at stage 0, 24.1 % at stage 1, 40.0 % at stage 2, and 40.2 % at advanced CKM. NAFLD was significantly associated with CKM progression (odds ratio = 2.01; 95 % confidence interval: 1.84-2.20) in ordinal logistic regression. During a median follow-up of 27.9 years, 3,772 deaths occurred. NAFLD was associated with a 26 % increased risk of all-cause mortality in multivariable Cox models; however, the association became non-significant after adjustment for specific components of CKM. Among participants with NAFLD, mortality risk increased stepwise with advancing CKM. Predicted CVD event risk demonstrated superior prognostic value than NAFLD fibrosis score and Fibrosis-4 score (area under the curve = 0.88). CKM stage significantly mediated the association between NAFLD and mortality, with a mediation proportion of 35.4 %.
Conclusions
NAFLD exhibits high comorbidity with CKM syndrome, and the high prevalence of NAFLD at CKM 0 highlights early metabolic risk. NAFLD is not an independent mortality predictor but accelerates CKM progression to increased mortality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine, Chongqing University, Chongqing, PR China.
- The First College of Clinical Medicine, Chongqing Medical University, Chongqing, PR China.
- Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Zitieren
APA
Liu, J., Gao, L., Chen, J., Li, Z., Zhao, W., Qin, S., Wen, X., & Zhang, D. (2025). Prevalence and long-term outcomes of NAFLD and cardiovascular-kidney-metabolic health in the United States. American Journal of Preventive Cardiology, 23, 101049. https://doi.org/10.1016/j.ajpc.2025.101049
Vancouver
Liu J, Gao L, Chen J, Li Z, Zhao W, Qin S, et al. Prevalence and long-term outcomes of NAFLD and cardiovascular-kidney-metabolic health in the United States. American Journal of Preventive Cardiology. 2025;23:101049. doi:10.1016/j.ajpc.2025.101049
BibTeX
@article{Liu2025,
author = {Liu, Jian and Gao, Lei and Chen, Junlong and Li, Zhenghao and Zhao, Wenhang and Qin, Shiwei and Wen, Xuesong and Zhang, Dongying},
title = {Prevalence and long-term outcomes of NAFLD and cardiovascular-kidney-metabolic health in the United States},
journal = {American Journal of Preventive Cardiology},
year = {2025},
volume = {23},
pages = {101049},
doi = {10.1016/j.ajpc.2025.101049}
}
EUVIMED